A Study of Movement Disorders Using the QMAT At-Home Testing Device
- Parkinson s disease (PD) affects half a million Americans, causing slow movements, tremors, stiffness, and trouble walking. Currently, these symptoms are measured by physical exam, but this is unreliable and requires an office visit. Researchers want to study a different way to measure PD symptoms, using a home-testing machine called a QMAT device. It can test how quickly someone moves doing different tasks. Researchers will study how this testing compares to physical exam testing and whether the device can detect changes in PD symptoms over time.
- To see if a home testing device can be used to evaluate Parkinson s disease symptoms.
- Adults at least 18 years old with PD.
- Participants will have about 22 clinic visits over 5 years. Each visit will take up to 3 hours. Visits will be scheduled along with visits for another study.
- At visit 1, participants will learn to use the QMAT device and how to send testing information to the clinic by computer. The device has a computer screen, some buttons, and some pegs. Participants will get a device to take home and any accessories.
- Participants will learn 2 QMAT tests. For one, they will press keys as fast as possible. For the other, they will move pegs into holes. The tests will take a total of about 20 minutes.
- Participants will take both tests at home, 2 times on the same day each week, once before their medication, once after.
- A study coordinator will monitor the participant s computer data and discuss the at-home testing at the clinic visits.
|Study Design:||Time Perspective: Prospective|
|Official Title:||A Longitudinal Study Assessing the Pathophysiology of Movement Disorders Utilizing the QMAT at Home Testing Device|
- Mean speed of keystrokes on a repetitive finger movement [ Time Frame: 5 years follow up ] [ Designated as safety issue: No ]
- Mean speed of movement on a peg movement task [ Time Frame: 5 years follow up ] [ Designated as safety issue: No ]
|Study Start Date:||June 2013|
|Estimated Study Completion Date:||September 2022|
|Estimated Primary Completion Date:||September 2022 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01905839
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Codrin I Lungu, M.D.||National Institute of Neurological Disorders and Stroke (NINDS)|